Search Results
Your search for Monica Morrow, MD matches 11 pages
Showing 1 - 11
Monica Morrow, MD, on View From the Trenches: What Will You do on Monday Morning?
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center reviews lessons learned from top abstracts, including how to tailor the extent of local therapy to minimize morbidity, the diminishing role of axillary lymph node dissection, long-term sequelae of breast surgical procedures, and the need...
Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer
In a study reported in JAMA Oncology, Morrow and colleagues found that surgeon acceptance of more limited surgery in early breast cancer was more likely among high-volume surgeons and those preferring a surgical margin of “no ink on tumor.” As noted by the authors, the American College ...
Trends in Surgery After Initial Lumpectomy for Breast Cancer
In a study reported in JAMA Oncology, Morrow et al found that the rates of surgery after initial lumpectomy for stage I or II breast cancer have decreased with dissemination of guidelines advocating a minimal negative surgical margin. A 2014 consensus statement of the Society of Surgical Oncology...
Monica Morrow, MD: Brinker Award Lecture Summary on Changing Paradigms in Local Therapy of Breast Cancer
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture on modifying local therapy to decrease the burden of cancer treatment.
New SSO, ASTRO, and ASCO Joint DCIS Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health System Costs
Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole breast irradiation. The new guideline has the potential to save many women from unnecessary...
Breast Cancer Symposium: Recurrence Rates for Ductal Carcinoma in Situ Treated Between 1978–2010
A new retrospective analysis explored local recurrence rates for women with ductal carcinoma in situ (DCIS) treated between 1978 and 2010. In the research (Abstract 32) by Van Zee et al, to be presented September 25 at the 2015 Breast Cancer Symposium, in San Francisco, investigators evaluated a...
Racial/Ethnic Barriers to Breast Reconstruction After Mastectomy for Breast Cancer
In a study reported in JAMA Surgery, Morrow et al found that breast reconstruction after mastectomy for breast cancer largely reflects patient demand, with the majority of women being satisfied with the decision-making process. However, black women were significantly less likely to have...
SSO-ASTRO Consensus Guideline: Margins Wider Than 'No Ink on Tumor' Do Not Further Reduce Risk of Ipsilateral Breast Tumor Recurrence
The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) formed a multidisciplinary expert panel in 2013 to examine the relationship between surgical margin width and ipsilateral breast tumor recurrence and develop guidelines on margins for breast-conserving...
Wider Surgical Margins Do Not Appear To Reduce Local Recurrence Rates in Triple-Negative Breast Cancer
Wider surgical margins did not reduce the rate of local recurrence in women with triple-negative breast cancer treated with breast-conserving therapy, according to the results of a study published in the Annals of Surgical Oncology. Pilewskie et al reported that their data support the definition of ...
Could MRI Be a Better Breast Cancer Screening Tool Than Mammography?
German investigators reported at the 2013 Breast Cancer Symposium in San Francisco that an abridged magnetic resonance imaging (MRI) protocol can accurately detect cancers among women whose mammographic screenings were negative (Abstract 1). MRI, therefore, may reveal the type of tumor that...
Experts Discuss Challenges in Counseling Patients About Contralateral Prophylactic Mastectomy
Many factors play into why women diagnosed with breast cancer often choose overly aggressive treatment even when there is little evidence to show clinical benefit: the shock and fear of suddenly being confronted with a major health threat, the impression of having to make treatment decisions...
